NASDAQ:GLMDGalmed Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Galmed Pharmaceuticals Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $5.43 +0.71 (+15.04 %) (As of 07/15/2020 03:00 PM ET) Add Compare Share Today's Range$5.19Now: $5.43▼$6.2950-Day Range$4.54MA: $4.99▼$5.8152-Week Range$3.02Now: $5.43▼$7.38Volume476,004 shsAverage Volume82,977 shsMarket Capitalization$114.69 millionP/E RatioN/ADividend YieldN/ABeta2.51 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. The company is develops Aramchol, an oral therapy, which is completed ARREST Phase IIb clinical study for the treatment of patients with overweight or obesity, and who are pre-diabetic or type-II-diabetic with non-alcoholic steato-hepatitis. It also evaluates Aramchol through ARRIVE Study, a proof-of-concept Phase IIa clinical trial, with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. The company was founded in 2000 and is headquartered in Tel Aviv, Israel.Read More Beat the Market (BTM) Rank™ 4.4 Analyst's Opinion Consensus RatingGalmed Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 8 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $20.22, Galmed Pharmaceuticals has a potential upside of 272.3% from its current price of $5.43.Amount of Analyst CoverageGalmed Pharmaceuticals has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.3 Community Rank Outperform VotesGalmed Pharmaceuticals has received 429 “outperform” votes. (Add your “outperform” vote.)Underperform VotesGalmed Pharmaceuticals has received 230 “underperform” votes. (Add your “underperform” vote.)Community SentimentGalmed Pharmaceuticals has received 65.10% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Galmed Pharmaceuticals and other stocks. Vote “Outperform” if you believe GLMD will outperform the S&P 500 over the long term. Vote “Underperform” if you believe GLMD will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldGalmed Pharmaceuticals does not currently pay a dividend.Dividend GrowthGalmed Pharmaceuticals does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Galmed Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 33.85% of the stock of Galmed Pharmaceuticals is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Galmed Pharmaceuticals are expected to decrease in the coming year, from ($1.28) to ($1.55) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Galmed Pharmaceuticals is -5.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Galmed Pharmaceuticals is -5.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGalmed Pharmaceuticals has a P/B Ratio of 1.65. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 4.4Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.54 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GLMD Previous Symbol CUSIPN/A CIK1595353 Webwww.galmedpharma.com Phone972-3693-8448Debt Debt-to-Equity RatioN/A Current Ratio11.57 Quick Ratio11.57Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$2.04 million Price / Sales56.22 Cash FlowN/A Price / Cash FlowN/A Book Value$3.30 per share Price / Book1.65Profitability EPS (Most Recent Fiscal Year)($0.97) Net Income$-20,460,000.00 Net MarginsN/A Return on Equity-31.47% Return on Assets-29.34%Miscellaneous Employees17 Outstanding Shares21,113,000Market Cap$114.69 million Next Earnings Date8/3/2020 (Estimated) OptionableOptionable NASDAQ:GLMD Rates by TradingView Receive GLMD News and Ratings via Email Sign-up to receive the latest news and ratings for GLMD and its competitors with MarketBeat's FREE daily newsletter. Galmed Pharmaceuticals (NASDAQ:GLMD) Frequently Asked Questions How has Galmed Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Galmed Pharmaceuticals' stock was trading at $4.21 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, GLMD stock has increased by 29.0% and is now trading at $5.4320. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Galmed Pharmaceuticals? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Galmed Pharmaceuticals in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Galmed Pharmaceuticals. When is Galmed Pharmaceuticals' next earnings date? Galmed Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Galmed Pharmaceuticals. How were Galmed Pharmaceuticals' earnings last quarter? Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) issued its quarterly earnings results on Thursday, May, 14th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.37) by $0.08. View Galmed Pharmaceuticals' earnings history. What price target have analysts set for GLMD? 10 Wall Street analysts have issued 1-year target prices for Galmed Pharmaceuticals' shares. Their forecasts range from $8.00 to $33.00. On average, they anticipate Galmed Pharmaceuticals' share price to reach $20.22 in the next year. This suggests a possible upside of 272.3% from the stock's current price. View analysts' price targets for Galmed Pharmaceuticals. Has Galmed Pharmaceuticals been receiving favorable news coverage? Media coverage about GLMD stock has been trending extremely negative recently, InfoTrie reports. The research group identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Galmed Pharmaceuticals earned a media sentiment score of -4.0 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 3.0 out of 10, meaning that recent media coverage is unlikely to have an impact on the company's share price in the near future. View the latest news about Galmed Pharmaceuticals. Who are some of Galmed Pharmaceuticals' key competitors? Some companies that are related to Galmed Pharmaceuticals include Crinetics Pharmaceuticals (CRNX), Viking Therapeutics (VKTX), Clovis Oncology (CLVS), BioSpecifics Technologies (BSTC), Emisphere Technologies (EMIS), Mirum Pharmaceuticals (MIRM), AC Immune (ACIU), Protagonist Therapeutics (PTGX), TherapeuticsMD (TXMD), Prothena (PRTA), Fulcrum Therapeutics (FULC), BioDelivery Sciences International (BDSI), Ocular Therapeutix (OCUL), Satsuma Pharmaceuticals (STSA) and XBiotech (XBIT). View all competitors. What other stocks do shareholders of Galmed Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Galmed Pharmaceuticals investors own include Opko Health (OPK), Viking Therapeutics (VKTX), SCYNEXIS (SCYX), Rite Aid (RAD), TherapeuticsMD (TXMD), Sorrento Therapeutics (SRNE), Micron Technology (MU), Corbus Pharmaceuticals (CRBP), Exelixis (EXEL) and Immunomedics (IMMU). Who are Galmed Pharmaceuticals' key executives? Galmed Pharmaceuticals' management team includes the following people: Mr. Allen Baharaff, Co-Founder, CEO, Pres & Director (Age 55, Pay $784.86k)Mr. Yohai Stenzler, CFO & Controller (Age 37, Pay $155.34k)Mr. Guy Nehemya, Chief Operating Officer (Age 35, Pay $165.43k)Dr. Liat Hayardeny, Chief Scientific Officer (Age 53, Pay $242.52k)Dr. Tali Gorfine, Chief Medical Officer (Age 50, Pay $242.28k) What is Galmed Pharmaceuticals' stock symbol? Galmed Pharmaceuticals trades on the NASDAQ under the ticker symbol "GLMD." How do I buy shares of Galmed Pharmaceuticals? Shares of GLMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Galmed Pharmaceuticals' stock price today? One share of GLMD stock can currently be purchased for approximately $5.43. How big of a company is Galmed Pharmaceuticals? Galmed Pharmaceuticals has a market capitalization of $114.69 million and generates $2.04 million in revenue each year. The biopharmaceutical company earns $-20,460,000.00 in net income (profit) each year or ($0.97) on an earnings per share basis. Galmed Pharmaceuticals employs 17 workers across the globe. What is Galmed Pharmaceuticals' official website? The official website for Galmed Pharmaceuticals is www.galmedpharma.com. How can I contact Galmed Pharmaceuticals? Galmed Pharmaceuticals' mailing address is 16 TIOMKIN STREET, TEL AVIV L3, 6578317. The biopharmaceutical company can be reached via phone at 972-3693-8448 or via email at [email protected] This page was last updated on 7/15/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
